15:49:08 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-08-07 Kvartalsrapport 2024-Q2
2024-06-06 Ordinarie utdelning BIOBV 0.00 EUR
2024-06-05 Årsstämma 2024
2024-02-14 Bokslutskommuniké 2023
2023-08-09 Kvartalsrapport 2023-Q2
2023-06-15 Ordinarie utdelning BIOBV 0.00 EUR
2023-06-14 Årsstämma 2023
2023-03-22 Bokslutskommuniké 2022
2022-08-10 Kvartalsrapport 2022-Q2
2022-06-16 Ordinarie utdelning BIOBV 0.00 EUR
2022-06-15 Årsstämma 2022
2022-03-09 Extra Bolagsstämma 2022
2022-02-16 Bokslutskommuniké 2021
2021-08-11 Kvartalsrapport 2021-Q2
2021-04-22 Ordinarie utdelning BIOBV 0.00 EUR
2021-04-21 Årsstämma 2021
2021-02-17 Bokslutskommuniké 2020
2020-08-12 Kvartalsrapport 2020-Q2
2020-04-23 Ordinarie utdelning BIOBV 0.00 EUR
2020-04-22 Årsstämma 2020
2020-02-19 Bokslutskommuniké 2019
2019-08-14 Kvartalsrapport 2019-Q2
2019-04-25 Ordinarie utdelning BIOBV 0.00 EUR
2019-04-24 Årsstämma 2019
2019-02-20 Bokslutskommuniké 2018
2018-08-22 Kvartalsrapport 2018-Q2
2018-08-16 Extra Bolagsstämma 2018
2018-04-26 Ordinarie utdelning BIOBV 0.00 EUR
2018-04-25 Årsstämma 2018
2018-02-28 Bokslutskommuniké 2017
2017-07-27 Kvartalsrapport 2017-Q2
2017-04-27 Ordinarie utdelning BIOBV 0.00 EUR
2017-04-26 Årsstämma 2017
2017-02-02 Bokslutskommuniké 2016
2016-10-20 15-10 2016-Q3
2016-08-10 Kvartalsrapport 2016-Q2
2016-05-12 Kvartalsrapport 2016-Q1
2016-04-26 Ordinarie utdelning BIOBV 0.00 EUR
2016-04-25 Årsstämma 2016
2016-02-25 Bokslutskommuniké 2015
2015-10-22 Kvartalsrapport 2015-Q3
2015-08-20 Kvartalsrapport 2015-Q2
2015-05-07 Kvartalsrapport 2015-Q1
2015-04-21 Ordinarie utdelning BIOBV 0.00 EUR
2015-04-20 Årsstämma 2015
2015-02-26 Bokslutskommuniké 2014
2014-10-23 Kvartalsrapport 2014-Q3
2014-08-21 Kvartalsrapport 2014-Q2
2014-05-08 Kvartalsrapport 2014-Q1
2014-04-15 Ordinarie utdelning BIOBV 0.72 EUR
2014-04-14 Årsstämma 2014
2014-02-27 Bokslutskommuniké 2013
2013-10-24 Kvartalsrapport 2013-Q3
2013-08-08 Kvartalsrapport 2013-Q2
2013-04-25 Kvartalsrapport 2013-Q1
2013-04-09 Ordinarie utdelning BIOBV 0.50 EUR
2013-04-08 Årsstämma 2013
2013-02-27 Bokslutskommuniké 2012
2012-10-25 Kvartalsrapport 2012-Q3
2012-08-16 Kvartalsrapport 2012-Q2
2012-04-26 Kvartalsrapport 2012-Q1
2012-04-12 Ordinarie utdelning BIOBV 1.00 EUR
2012-04-11 Årsstämma 2012
2012-02-29 Bokslutskommuniké 2011
2011-11-23 Extra Bolagsstämma 2011
2011-10-20 Kvartalsrapport 2011-Q3
2011-08-18 Kvartalsrapport 2011-Q2
2011-04-28 Kvartalsrapport 2011-Q1
2011-04-14 Ordinarie utdelning BIOBV 0.00 EUR
2011-04-13 Årsstämma 2011
2011-03-01 Bokslutskommuniké 2010
2010-04-26 Ordinarie utdelning BIOBV 0.00 EUR
2009-04-21 Ordinarie utdelning BIOBV 0.00 EUR
2008-04-22 Ordinarie utdelning BIOBV 0.00 EUR
2007-04-20 Ordinarie utdelning BIOBV 0.00 EUR
2006-04-21 Ordinarie utdelning BIOBV 0.00 EUR
2005-04-22 Ordinarie utdelning BIOBV 0.00 EUR
2004-04-16 Ordinarie utdelning BIOBV 0.00 EUR
2003-04-10 Ordinarie utdelning BIOBV 0.00 EUR
2002-04-02 Ordinarie utdelning BIOBV 0.00 EUR
2001-03-28 Ordinarie utdelning BIOBV 0.00 EUR
2000-04-07 Ordinarie utdelning BIOBV 0.00 EUR
1999-04-22 Ordinarie utdelning BIOBV 0.00 EUR

Beskrivning

LandFinland
ListaSmall Cap Helsinki
SektorHälsovård
IndustriMedicinteknik
Biohit är verksamt inom medicinteknik. Bolaget utvecklar och tillverkar laboratorieutrustning, förnödenheter samt diagnostiska analyssystem anpassade för forskning, vård och industrilaboratorium. Utöver huvudverksamheten erbjuds teknisk support, underhåll samt utbildningstjänster inom nämnt arbetsområde. Störst verksamhet återfinns inom den nordiska marknaden. Bolaget har sitt huvudkontor i Helsingfors.
2023-05-24 11:00:00

Biohit Oyj Stock Exchange Release May 24, 2023 at 12:00 am local time (EEST)

Biohit Oyj shareholders are invited to attend the company's Annual General Meeting to be held on Wednesday, June 14, 2023 starting at 2:00 pm at the Helsinki Stock Exchange Building, for which the address is Fabianinkatu 14, 00100 Helsinki. The reception of registered participants and the distribution of voting papers at the meeting venue will start at 1:00 pm.

A. Matters on the agenda of the Annual General Meeting

1.      Opening of the meeting

2.      Calling the meeting to order

3.      Election of persons to inspect the Minutes and supervise the counting of votes

4.      Recording the legality of the meeting

5.      Recording the attendance at the meeting and the list of votes

6.      Presentation of the Financial Statements, the Report of the Board of Directors and the Auditor's Report for 2022

7.      Adoption of the Financial Statements

The Board of Directors proposes that the Annual General Meeting adopts the annual accounts. The Auditor of the Company has supported the adoption of the annual accounts.

8.      Resolution on the use of the profit shown on the Balance Sheet and on dividend payment / Board's proposal for distributions of profit

The Board of Directors proposes to the Annual General Meeting that the result for the financial period ended on 31st of December 2022 be recorded in the profit and loss account.

The parent company's distributable funds (unrestricted equity) on 31 December 2022 are EUR 4711504,69, of which the period net profit is EUR 934640,55. The Board of Directors proposes to the Annual General Meeting that no dividend be paid for the financial year.

9.      Resolution on the discharge of the members of the Board of Directors and the CEO from liability

10.  Resolution on the number and remuneration of the members of the Board of Directors

Shareholders representing more than 50% of the voting rights conferred by all company's shares have announced their intention to propose to the Annual General Meeting that the number of Board members be confirmed at five (5).These shareholders have announced their intention to propose to the Annual General Meeting that the meeting remuneration be paid to the Board members and the Chairman be unchanged as follows: EUR 1,500 to the Chairman and EUR 1,500 to other Board members.

11.  Election of Board Members

Shareholders representing more than 50% of the voting rights conferred by all company's shares have announced their intention to propose to the Annual General Meeting that the following persons be elected to the Company's Board of Directors until the end of the next Annual General Meeting: Liu Feng, Kalle Härkönen, Lea Paloheimo, Vesa Silaskivi and Osmo Suovaniemi.All candidates have given their consent to the election. More information on member candidates is available on May 24, 2023 on the company website at https://www.biohithealthcare.com/en/investors/shareholder-meetings/annual-general-meeting-2023/.

12.  Remuneration Report

The Board of Directors proposes that the Remuneration Report of the Company's governing bodies for 2022 be approved. The resolution is advisory in accordance with the Finnish Limited Liability Companies Act.

The Remuneration Report is available on the Company's website athttps://www.biohithealthcare.com/en/investors/renumeration-reports/.

13.  Resolution on the remuneration of the Auditor

The Board of Directors proposes to the Annual General Meeting that the Auditor to be elected be remunerated in according to an invoice approved by the Company.

14.  Election of the Auditor

Shareholders representing more than 50% of the voting rights conferred by all company's shares have announced that Authorized Public Accountants PricewaterhouseCoopers Oy be elected as Auditors until the end of the next Annual General Meeting. PricewaterhouseCoopers Oy has informed the Company that Authorized Public Accountant Tiina Puukkoniemi is going to act as the auditor with the principal responsibility

15.  Closing of the meeting

The proposals for the decisions on the matters on the agenda of the Annual General Meeting as well as this notice are available on Biohit Oyj's website athttps://www.biohithealthcare.com/en/investors/shareholder-meetings/annual-general-meeting-2023/. The annual report, the group's annual report, the report of the Board of Directors, and the Auditor's report as well as the remuneration report of Biohit Oyj are available on the aforementioned website as from 24 May 2023 at the latest. The proposals for decisions and other documents mentioned above will also be available for inspection at the General Meeting.

The minutes of the meeting will be available on theaforementioned websiteas from 19 June 2023 at the latest.

C.     Instructions for the participants at the Annual General Meeting

1.      The right to participate and registration

Shareholders who on the Annual General Meeting record date of Friday 2 June 2023 are registered in the Company's shareholder register maintained by Euroclear Finland Oy have the right to participate in the Annual General Meeting. Any shareholder whose shares are registered on his/her personal Finnish book-entry account is registered in the company's shareholder register.

Registration for the meeting will begin on 29 May 2023 at 10.00 am EEST. A shareholder entered in the Company's shareholder register, who wishes to participate in the Annual General Meeting, must register latest on Friday 9 June 2022 at 4.00 pm EEST, by which time the registration needs to be received. It is possible to register for the General Meeting:

a)      through the Company's website athttps://www.biohithealthcare.com/en/investors/shareholder-meetings/annual-general-meeting-2023/. If the shareholder is an individual, electronic registration requires strong electronic authentication, which takes place either with a Finnish bank ID or a Finnish mobile certificate.
If the shareholder is a legal person, electronic registration requires either strong electronic authentication, or the book-entry account number and Business ID of the shareholder; or

b)      by email to yhtiokokous@biohit.fior by calling +358 20 770 6889.

When registering for the meeting, the following details shall be provided: the shareholder's name, personal identity number or Business ID, address, telephone number as well as the name of any proxy representative or assistant to be used, and the personal identity number of the proxy representative. The personal data given by shareholders to Biohit Oyj will only be used in connection with the General Meeting and for processing the necessary registrations.

The shareholder, their representative or proxy must be able to prove their identity and/or right of representation at the meeting, where necessary.

2.      Shareowners with nominee-registered shares

Shareowners with nominee-registered shares have the right to participate in the Annual General Meeting on the basis of the shares held on the record date of the Annual General Meeting, i.e. 2 June 2023, that would give them the right to be included in the Company's shareholder register maintained by Euroclear Finland Oy. Attendance also requires that the shareholder is temporarily entered in the Company's shareholder register maintained by Euroclear Finland Oy by 10:00 am EEST on Friday 9 June 2023 at the latest. For shareholders with nominee-registered shares, this is considered registration for the Annual General Meeting. Any changes in the ownership of shares that occur after the record date of the General Meeting do not affect the right to participate in the General Meeting or the number of votes a shareholder may cast.

Shareholders with nominee-registered shares are encouraged to request without delay the necessary instructions concerning temporary registration with the Company's shareholder register, issuing proxy documents, and registration for the Annual General Meeting from their custodian bank. The account management organization of the custodian bank must register a shareholder with nominee-registered holdings, who wants to participate in the Annual General Meeting, temporarily into the Company's Shareholder Register at the latest by the time stated above. Further information is also available on the Company's website at https://www.biohithealthcare.com/en/investors/shareholder-meetings/annual-general-meeting-2023/.

3.      Proxy representatives and powers of attorney

A shareholder may participate in the Annual General Meeting by way of proxy representation. A proxy representative shall produce a dated proxy document or otherwise in a reliable manner demonstrate their right to represent the shareholder at the Annual General Meeting. When a shareholder participates in the Annual General Meeting by means of several proxy representatives, representing the shareholder with shares in different book-entry accounts, the shares by which each proxy representative represents the shareholder shall be identified in connection with the registration for the Annual General Meeting.

Possible proxy documents should be delivered by regular mail to Yhtiökokous, Laippatie 1, 00880 Helsinki tai or by e-mail to yhtiokokous@biohit.fibefore the end of the registration period. In addition to delivering the documents of proxy, the shareholder or his/her proxy shall ensure that they are registered for the General Meeting in the manner described above in this notice.

4.      Other information

The language used in the meeting shall be Finnish.

A shareholder has the right to ask questions referred to in Chapter 5, Section 25 of the Finnish Limited Liability Companies Act with respect to the matters to be considered at the Meeting.

Any changes in the ownership of shares that occur after the record date of the General Meeting do not affect the right to participate in the General Meeting or the number of votes a shareholder may cast.

The information on the Annual General Meeting required by the Finnish Limited Liability Companies Act and the Securities Market Act is available on the Company's website at https://www.biohithealthcare.com/en/investors/shareholder-meetings/annual-general-meeting-2023/.

On 24 May 2023, the date of the notice of the Annual General Meeting, the share capital of Biohit Oyj consists of a total of 15113593 shares. The shares are divided into Series A and Series B. The total number of Series A shares is 2975500 producing a total of 59510000 votes, while the total number of Series B is 12138093 producing a total of 12138093 votes.

Helsinki, 24 May 2023

Biohit Oyj
The Board of Directors

Additional information:

Chairperson of the Board Lea Paloheimo, Biohit Oyj
puh. +358 9 773861
investor.relations@biohit.fi (https://www.globenewswire.com/Tracker?data=PwLdjOY00JDDDIZWV3-Lmeo6BH0fdQLM9yb1zBCDsvvX-r0uSzYg-yFcIS4McyMqrexc2-b46w6N-T2KR80k2vhsJRrNh8QYbGyzEMovjieSxhRK_IlxSQtgzqqqLIMv)
www.biohit.fi (https://www.globenewswire.com/Tracker?data=c5rWyQltbzVNETEAzPUZ5V5P28BlbjsqHU8yYzA4G7utxndHN0uhz7--QXorafAcibRMjzoynLtac5BbE-kt-Q==)

Biohit Oyj in Brief

Biohit Oyj is a globally operating Finnish biotechnology company. Biohit's mission is "Innovating for Health" - we produce innovative products and services to promote research and early diagnosis. Biohit is headquartered in Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit's Series B share (BIOBV) is quoted on Nasdaq Helsinki in the Small cap/Healthcare group. www.biohithealthcare.com (https://www.globenewswire.com/Tracker?data=c5rWyQltbzVNETEAzPUZ5WLkdGhFEQ1oTBo35iEHNX8xhFJ8UXxKcBfwNUj1oaJLkJWDIfhT0_qN_43uOPrHsIIWy25pE_7iX8aTY-nisGmlggNS87UH1ViJkQ-0ezca).